第一作者机构：[1]Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China
推荐引用方式(GB/T 7714)：
Zhang Xiangmei,Zhang Shuo,Li Zhong,et al.Pyrotinib combined with EC-TH neoadjuvant therapy for patients with HER2-positive breast cancer: A multicenter, randomized, phase II, open-label trial[J].JOURNAL OF CLINICAL ONCOLOGY.2022,40(16):doi:10.1200/JCO.2022.40.16_suppl.e12604.
APA：
Zhang, Xiangmei,Zhang, Shuo,Li, Zhong,Niu, Fengling,Cai, Haifeng...&Liu, Yunjiang.(2022).Pyrotinib combined with EC-TH neoadjuvant therapy for patients with HER2-positive breast cancer: A multicenter, randomized, phase II, open-label trial.JOURNAL OF CLINICAL ONCOLOGY,40,(16)
MLA：
Zhang, Xiangmei,et al."Pyrotinib combined with EC-TH neoadjuvant therapy for patients with HER2-positive breast cancer: A multicenter, randomized, phase II, open-label trial".JOURNAL OF CLINICAL ONCOLOGY 40..16(2022)
医学